Plain-language definitions for the evidence terms and classifications used across WhichPeps.
Strong clinical/regulatory evidence exists for one or more authorised products and defined indications. · State the authorised indication and product; explicitly separate unverified non-authorised products.
FDA approval exists for a narrowly defined use/product. · Do not broaden the approval to wellness, performance or generic research vials.
Controlled human efficacy data exist but the compound remains investigational. · Report study population, endpoints and adverse events; do not say 'approved' or 'proven'.
Human exposure/PK/PD studies exist but clinical outcomes are not established. · Explain what changed biologically, not that it treats a condition.
Small, older or region-specific studies exist with limited independent replication. · Use cautious wording and highlight study-quality/generalizability limitations.
Most evidence is animal/cell based with little human clinical data. · Lead with the evidence limitation before describing proposed effects.
No meaningful therapeutic human evidence identified. · Describe laboratory/animal findings only; never convert them into a human benefit claim.
Human endogenous/biomarker data may exist, but administered-drug evidence is absent. · State clearly that endogenous biology is not evidence for injected/supplemented use.
The named commercial combination has not been clinically tested as a blend. · Summarise components separately and state that synergy/safety of the blend is unestablished.
Active ingredient or exact blend composition cannot be verified from source. · Do not publish benefits until label/COA/manufacturer information is obtained.
Diluent/reconstitution/lab item rather than therapeutic active. · Information page only; no therapeutic-benefit language.